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Objectives: To respond to the ‘quality assurance’ of the EQ-5D-5L value set for England study.
Methods:We provide a point-by-point response to the issues raised by the authors of the quality assurance paper, drawing on
theoretical arguments, empirical analyses and practical considerations.
Results: We provide evidence to show that many of the points made by the authors of the quality assurance are misleading,
suggest misunderstandings, or are irrelevant.
Conclusions: The modelling approaches which were used appropriately address the characteristics of the data and provide a
reasonable representation of the average stated preferences of general public in England. We provide reflections on the
conduct of stated preference studies, and suggestions for the way forward.
Keywords: discrete choice experiment, EQ-5D, quality assurance, time trade-off, valuation, value set.
VALUE HEALTH. 2020; -(-):-–-Introduction
The EQ-5D-5L value set for England1,2 has potentially impor-
tant implications for healthcare decisions that are informed by
EQ-5D-5L data. Among those are recommendations about the
reimbursement of new technologies made by the National Insti-
tute for Health and Care Excellence (NICE). It is therefore entirely
appropriate that it be subjected to external review before being
recommended for use.
In 2017 the UK Department of Health and Social Care
commissioned a “quality assurance” from the Economic Evalua-
tion Policy Research Unit (EEPRU), which is summarized in an
article3 in this issue of Value in Health. The authors of the article
(hereafter, “EEPRU authors”) concluded that the EQ-5D-5L value
set estimates “fall short of the required standards for decision
making,” citing deficiencies in both the quality and the subsequent
modeling of the data. The points made by the authors principally
focus on the English value set but have implications for all EQ-5D-
5L value sets developed using the EuroQol Group’s international
protocol.4of interest: All authors are members of the EuroQol Group. The views exp
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cess article under the CC BY-NC-ND license (http://creativecommons.org/lic
doi.org/10.1016/j.jval.2019.10.013NICE’s current advice5 to those who have collected EQ-5D-5L
data is not to use the value set reported in our articles in Health
Economics1,2 but rather to map between the EQ-5D-5L and EQ-5D-
3L (using the crosswalk developed by van Hout et al6) and to
continue to use the “Measurement and Valuation of Health”
(MVH) UK value set for the EQ-5D-3L.7,8 In effect, this advice in-
volves mapping to an inferior and less sensitive descriptive sys-
tem9,10 and applying a value set that is more than 20 years old and
has characteristics that have not been replicated elsewhere
(a point we will return to later).
In this article, we provide evidence to show that many of the
points made by the EEPRU authors are misleading, suggest mis-
understandings, or are irrelevant. We summarize the key points
the authors made and respond briefly to each. We provide results
from additional analyses to support our assertion that the
modeling approaches were used appropriately to address the
characteristics of the data and provide a reasonable representation
of the average stated preferences of the general public in England.
We conclude with some reflections on the conduct of stated
preference studies and provide suggestions for the way forward.ressed do not necessarily reflect those of the EuroQol Group.
ne School of Population and Global Health, Level 4, 207 Bouverie Street, the
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The Design and Coverage
The design is inadequate because it provides inadequate coverage of
the states in the EQ-5D-5L descriptive system. The design followed the
international protocol (EQ-VT) developed by the EuroQol Group,
which has been used in many studies to date.11–14 Value sets
generated from this protocol have been accepted for use by other
national healthcare decisionmakers, such as in The Netherlands.15 As
outlined by Oppe and van Hout,16 a blocked design was used to
achieve a mix of states with respect to severity level representation.
The design comprised 10 blocks of 10 health states. Each block
included the worst health state in the descriptive system (55555)
and 1 of 5 of the least severe states. This left 8 health states per block
(80 states in total) to be generated. These 80 health states were
selected using Monte Carlo simulation, demanding orthogonality.
The set with the best results in terms of level balance and predictive
power was chosen to allow the estimation of all severity levels from
across the five dimensions. The discrete choice experiment (DCE)
design is similarly based on optimal design procedures.16
The fact that the final time trade-off (TTO) design only included
2.75% of all possible 5L health states and the final DCE design
included 0.01% of all potential pairwise comparisons has very
limited relevance given the purpose of the study, which was to
produce values for all 3125 states. This required experimental
designs with appropriate statistical characteristics based on well-
established mathematical theories rather than percentage
coverage of all possible combinations.
Other valuation studies, for different descriptive systems,
derived using various approaches to optimal designs, have similar
characteristics. For example, the value set for the SF-6D was based
on values generated using standard gamble for 249 states, ac-
counting for 1.38% of the 18 000 states described by the SF-6D.17 In
the valuation of the cancer-specific EORTC-8D using TTO, 85 states
were included, which was 0.1% of all possible states described.18
The Sample Size and Response Rate
There is no basis for the sample size and the response rate was
low, leading to potential bias.
The target sample size for this study, n = 1000, which has been
used in many EQ-5D-5L value set studies internationally, follows a
study design reported in detail by Oppe and van Hout.16
Interviews were conducted face-to-face in respondents’ homes.
Potential respondents were fully informed about the nature of the
questions and the length of the interview before consenting to
participate. To achieve a response rate of nearly 50% of those
identified is, we would argue, reasonable, given that each respon-
dent was being asked to allow a stranger into their home to query
them for around 45 minutes on questions about severe illness and
death. Most social surveys—which the EEPRU authors use as a
comparison—are very different in nature and do not include such
questions. A more appropriate comparison would be with other
health valuation studies. For example, Rowen et al report a
response rate of 40.3%.18 The current MVH value set is based on
interviews with 3395 individuals out of 6080 (55.8%) addresses
selected for sampling.19 Information on the individuals who did not
complete the interview in full was discarded as required by the
research ethics committee that approved the study, a common
procedure in interview-based studies and not a flaw of ours.
Data Anomalies and Flaws
The long, damning list of potentially problematic responses
include a number of strong judgments from the EEPRU authors asto what they think constitutes acceptable data. We would
emphasize that anyone who has been confronted with health state
valuation questions will appreciate that answering them is diffi-
cult. Errors and rounding (to whole number values) are to be
expected. Moreover, there are only 41 possible values in the TTO
tasks in the EQ-VT protocol (meaning that the greatest precision
that is possible is at 6 monthly intervals), and if a given respon-
dent values the worst health state at, say, 0.8 (thereby expressing a
strong preference for length of life compared to quality of life,
which is a legitimate response), there are only 5 values greater
than or equal to 0.8 left to choose from. Respondents who do so
are deemed by the EEPRU authors to be “problematic” and
described as producing data “flaws” and “anomalies.”
The EEPRU authors judge data as “problematic” when re-
spondents only give integer values. This kind of “lack of precision”
is quite common to stated preference exercises; it is not exclusive
to TTO valuation or to EQ-5D or to our study. It is important to
note that unless that lack of precision biases upwards or down-
wards the values that are elicited, this type of rounding has
virtually no impact on the average values calculated or modeled
for the health states, which was the purpose of the study.
The EEPRU authors also judge data as being “anomalies” in
cases where there is a logical ordering of health states, but the
same TTO value is given to both; however, such responses may
indicate entirely plausible and logical respondent preferences. For
example, a state may be logically worse, such as how “no prob-
lems with anything other than mild problems with mobility” is
logically worse than full health, but not worse enough for the
respondent to be willing to sacrifice any length of life to avoid it.
Consider another example: the EEPRU authors’ definition of
logical inconsistency deems as problematic a situation where a
value of –1 is given to both 55555 and a logically better state, such
as 44444. Yet –1 is a plausible value for 44444 and, because the
task is bounded at –1, it is not possible to assign 55555 a value
lower than –1. These methodological factors were considered in
the modeling process.
The key point here is that many of the responses the EEPRU
authors deem to be problematic—and upon which they base their
“gee whiz” figure of 94% of the data being flawed—may actually
represent people’s preferences.
In the abstract the EEPRU authors note that “47% of re-
spondents valued more than 20% of states inconsistently, double
the 3L rate” and that there is “strong evidence, both direct (self-
reported) and indirect (poor data quality), that many participants
found tasks difficult or did not engage effectively.”3 In responding
to this, it is worth noting that the percentage of responses in
which respondents can be inconsistent differs between the studies
slightly: 47% in the 5L study; 45% in the 3L study. It is also worth
noting that respondents in the MVH study valued 12 health states
using TTO, whereas respondents in the 5L study valued 10 health
states. Importantly, the EEPRU authors have not compared their
inconsistency findings to the entire MVH TTO data set—just to the
MVH data that were used in modeling once exclusions had been
made. We have done this, and the results for all respondents in
both studies (N = 3395 for the 3L vs N = 996 for the 5L) are re-
ported in the supplementary appendix. In the MVH study, 75.2% of
respondents had at least one inconsistency in their responses,
compared with 56.7% of respondents in the EQ-5D-5L value set for
England study.
To consider the impact of the problems that are present in the
data and represent “errors”—such as logical inconsistencies (as
conventionally defined, not as per the EEPRU authors’ definition)—
it is helpful to examine the distribution of residuals. These re-
siduals are the differences between predicted values and observed
values. In Figure 1, we distinguish between the distribution of
Figure 1. Residual distributions for inconsistent responses, consistent responses, and all responses. Distributions of residuals are near-
symmetric surrounding the value of zero.
Figure 2. Sequential residuals from 912 respondents. Each of
the 8,208 circle represents a pair of residuals from TTO task i and
i11 for a respondent. Fitted line is rather flat, which does not
support the EEPRU authors’ argument regarding strong
sequential dependency.
-- 3errors of the logically inconsistent responses, the non-inconsistent
responses, and the sum of those; and find a near-symmetric dis-
tribution of residuals surrounding zero.
Sequential Dependency
The EEPRU authors question the sequential dependency be-
tween responses from the same individual and therefore the es-
timations based on TTO data. For this, they analyze whether
“anomalies” are sequentially dependent. This is not the same as
analyzing whether responses are dependent. To address the latter,
we plot the 9 pairs of sequential residuals from the 10 responses
for each respondent. Figure 2 includes results from all 912 re-
spondents with each circle representing a pair of residuals from
TTO tasks i and i11 for a respondent. The 8208 (= 912 3 9) circles
are scattered through the figure with a rather flat fitted line. These
results do not support the EEPRU authors’ argument regarding
strong sequential dependency.Modeling
Inconsistency in the Distributional Assumptions Applied
to TTO and DCE Data
The EEPRU authors note that utility error terms are assumed
heteroscedastic and normally distributed in the TTO experiments
but homoscedastic and type 1 extreme value in the DCEs, andstate that this leads to mis-specification and inconsistent param-
eter estimates.3 First, on a theoretical level, TTO and DCE are
different tasks and therefore assuming a type I distribution (with
wider tails) for the one task and a normal error for the other is not
inconsistent. Why this would lead to inconsistent parameter
Figure 3. Predicted values for each individual. Each line in the figure shows the predicted values from each respondent based on the
heteroscedastic model with different slope. The results show that the variance increases with the increased level of severity for TTO
health states.
4 VALUE IN HEALTH - 2020estimates is not explained. Second, on a more practical level, the
parameter estimates using either a probit or logit model are
identical up to 3 digits, indicating that the assumption used does
not make any meaningful difference. We chose the assumption of
type I extreme value distribution because of the slightly lower
deviance information criterion statistics reported for the model.
It is observed that the variance surrounding the lower TTO
values is greater than that surrounding the higher TTO values. This
feature of the data is captured, in the heteroscedasticity models
for TTO data, by linking the variance to the expectations. For the
DCE data, the task is to rank order and choose between 2 health
states. There is no clear motivation, based on the observed binary
data, that one should also apply this relationship. Nevertheless, we
experimented with this using a probit specification in the DCE
models, assuming an identical relationship between the expected
value and the variance in the DCE data as in the TTO data and
found that this had a negligible effect on the parameter estimates.
Furthermore, it seems the EEPRU authors have misunderstood
our final hybrid model where the increasing variance with
decreasing health is captured by heterogeneity rather than het-
eroscedasticity. We discuss this point in the following section.
Confusing Weighting for Non-Response with Weighting
for Heteroscedasticity
We tried to capture the fact that there is increasing variance
with decreasing values in 2 distinct ways. First, we estimated
models where the variance is a function of the expected value ofthe health state (“heteroscedasticity models”). Second, we
assumed heterogeneity in the use of the scale as modeled by a
shape parameter (“heterogeneity models”). Three different
models for the heterogeneity of the shape parameter were used: a
normal, log normal, and multinomial distribution. Subsequently,
we also used a gamma distribution. Figure 3 illustrates this esti-
mating a different shape parameter for each individual. Here, re-
spondents are estimated to have the same relative weights for the
different dimensions and the levels on those dimensions but differ
with respect to the gradient towards dead and negative health
states. Assuming heterogeneity offers a very natural explanation
for why the variance around worse health states is greater.
We would emphasize that the final model is a model with
heterogeneity, not with heteroscedasticity. As such, the EEPRU
authors’ argument that we have mixed weighting with hetero-
scedasticity is inaccurate. Comparing the heterogeneity models
with and without weighting allows for an understanding of how
the weighting for age is introduced, and these are reported
in Appendix 1 in Supplemental Materials (found at https://doi.
org/10.1016/j.jval.2019.10.013).
Forcing Utility Decrements in the Ordering
The EEPRU authors note the potential drawbacks of using a
squared term to guarantee choice inconsistency. We tested many
priors and found that the choice of the prior distribution can make
quite a difference. For example, when using a gamma distribution,
decrements that were expected to be close to zero (on the basis of
Table 1. Observed and predicted values for the 5 mildest health states.
Health States Minimum 25% percentile Median Mean 75% percentile Maximum Predicted value
21111 0 0.9 0.95 0.8896 1 1 0.942
12111 0 0.8 0.95 0.8666 1 1 0.950
11211 0 0.9 0.95 0.8928 1 1 0.950
11121 –0.2 0.9 0.95 0.8854 1 1 0.937
11112 –0.65 0.8 0.95 0.8533 1 1 0.922
-- 5the unrestricted models) differed substantially from zero; a uni-
form distribution and using quadratic terms with normal distri-
butions showed similar results. We chose the latter and this
indeed results in jumps from positive to negative values in the
MCMC chains. Nevertheless, this does not give any problems in
the MCMC results for the relevant parameter values.
Censoring for TTO Data
The EEPRU authors state that “the interpretation of the limit at
1 as censoring is inappropriate. Censoring means that values
exceeding 1 are possible but unobserved.”3 We do not say or imply
that values greater than 1 are possible. Rather, the point is that
whereas for values along the continuum between 1 and –1 there is
an error distribution around the values, at the top end of the scale,
the error distribution is necessarily asymmetric, biasing central
estimates of the utility of very mild states downwards. Censoring
methods are used to explicitly address this asymmetry in the er-
rors. The rationale for doing so neither implies nor requires the
possibility of values . 1. Note also that we did not censor at 1 and
–1 but at 0.975 and -0.975. The EEPRU authors also suggest that
this censoring approach would bias estimates for the better health
states upwards. Table 1 presents the observed and predicted
values for the five mildest health states. There is no support for the
EEPRU authors’ claim that the estimates are biased.
Bayesian Modelling and Convergence Failure
The EEPRU authors provide a list of potential issues regarding
the Bayesian analysis process, ranging from the choice of priors to
the selection of initial values to the implementation of the simu-
lation estimator. The extent to which we could report all of our
analyses and results in peer-reviewed journal articles was limited.
We conducted sensitivity analyses to check the effect of substan-
tively different priors, initial values, multiple chains in the MCMC,
and frequentist approaches.
The EEPRU authors state that they “found no justification for
the choice of priors, nor any evidence of sensitivity analysis.”3 In
particular, their concern is with the prior distribution relating to
the probabilities of latent class membership. Our priors for the
probabilities of being members of each of the 3 latent groups are
0.3, 0.3, and 0.4, following a Dirichlet distribution. There is both a
theoretical and a practical note of relevance here. The theoretical
note is that the Dirichlet distribution is the natural conjugate of a
Dirichlet prior and a multinomial distribution. So suppose that
individuals can be in 3 groups and the prior follows a Dirichlet (a1,
a2, a3), and we find N1, N2, and N3 people observed in the 3 groups,
then the posterior distribution is again Dirichlet with a1 1 N1, a2,1
N2, a31 N3. Now, this is not completely applicable here, where the
group membership has to be estimated per individual, but it does
suggest, where N = 912, that priors below 1 are unlikely to be
informative. This is confirmed when exploring different priors in
our extensive sensitivity analyses. As might be expected, theestimated membership parameters are very robust and the pos-
terior distribution for the parameters is highly driven by the data
and not by the prior distribution. We therefore question the claim
that these priors are highly informative.
The EEPRU authors assert that they “found significant evidence
of lack of convergence, which is indicative of fundamental
shortcomings of the Devlin et al (2018) model specification.”3 In
selecting the best modeling method, we explored both Bayesian
and maximum likelihood approaches. Within the maximum
likelihood approach, we also included an iterative approach in
which we first estimated the maximum likelihood estimates
without heterogeneity (the standard parameters), then estimated
a shape parameter for each individual given the maximum like-
lihood parameters. We then, given the shape parameters, re-
estimated the standard parameters and then again re-estimated
the shape parameters. This was repeated until no improvement
was achieved. The estimates obtained in this way are strikingly
similar to the ones obtained using the multinomial model, the
log-normal model, and the (unpublished) gamma model for het-
erogeneity. We are more than happy to share the Convergence
Diagnosis and Output Analysis (CODA) results from our Bayesian
analyses—accompanied with a R-program—in the public domain
for judgment about whether convergence was achieved.
We shared 82 different BUG specification models and six R files
with the EEPRU authors as part of the quality assurance review
process, excluding models that were discarded and the many
sensitivity analyses. Run time of the most complex models with
2000 burn-in iterations and 5000 subsequent iterations is between
30 and 90minutes, and when running so manymodels, one obtains
an understanding of when a model converges. The EEPRU authors
only address the multinomial model and seem to have missed that
alternative specifications such as the log-normal model (or the
gamma-distribution for the shape parameter) lead to very similar
results without the admittedly temperamental—but quite logical—
results when identifying which group people belong to. This might
have tempered their claim that the model is unidentified. Indeed,
the multinomial model allows for 3 groups and the ultimate (TTO)
model is p1*(1-a1*x’b)1p2*(1-a2*x’b)1p3*(1-a3*x’b).
Althougha1 is forced tobealwaysclose to1,different combinations
b, a1, a2, and a3 can be obtained, all leading to the samepredictions, so
we question whether the lack of model identification is as much of a
problem as is suggested. Also we do not find any convergence prob-
lems in the parameters of the link function where the constant term,
following Bansback et al,20 is reflecting left-right bias.What This Means for the England EQ-5D-5L Value
Set
The pertinent question is whether our model is a fair reflection
of the average values for the English general public with respect to
the EQ-5D-5L. We believe that it is for the following reasons.
6 VALUE IN HEALTH - 2020First, answering questions about life and death and different
dimensions of health is difficult. People make errors, may be
inconsistent, and may show weak cognitive or empathic ability to
carry out TTO tasks. The question is whether the answers of such
individuals should be included and whether doing so would lead
to biased results. The results in Figure 1 show relatively symmetric
error distributions in both consistent and inconsistent answers,
giving no indication of any structural biases. Although the TTO
data may be “messier” than we would like, that has not affected
the central estimates of the values, the production of which is the
purpose of the exercise.
Second, recall that the data quality problems the EEPRU au-
thors allege relate only to the TTO data. Nevertheless, there is a
striking similarity in the findings from the TTO models and the
DCE models, as shown in the supplementary appendix. Both
methods point toward similar weights for the dimensions and
similar values for the levels within the dimensions. Our final
model, the one criticized by the EEPRU authors, is just one of many
that we tested. We ran hybrid models with maximum likelihood
methods (with heteroscedasticity and with heterogeneity) and
used Bayesian methods with the heterogeneity modeled using a
variety of distributions. The results of the various models were in
line with each other.
Third, the data show distributions that are broadly similar to
those from comparable studies undertaken in other countries. For
example, Abel Olsen et al report “striking similarities” between
the England value set and those of Canada, The Netherlands, and
Spain with respect to the relative importance of the 5 dimensions,
the relative utility decrements across the 5 levels, and the scale
length.21 We are confident that our statistical approach captures
the error distributions in such a way that the mean estimates are a
reliable representation of the average values of the general public.Future-Proofing NICE for Transitional Issues in
Switching Value Sets
The catalyst to the EEPRU review of the value set appears to
have been the observation that implementing the EQ-5D-5L value
set would lead to different estimates of quality-adjusted life-year
gains and incremental cost-effectiveness ratios compared with the
widely used MVH value set. Therefore there were concerns about
consistency in health technology assessment (HTA) decisions.
The EEPRU authors provide 3 references to their own work
showing that economic evaluations undertaken using 5L rather
than 3L are likely to generate very different results. Their research
confirms that new technologies that improve quality of life
appear less cost-effective if health gains are valued using 5L rather
than 3L, whereas technologies that extend life can appear more
cost-effective.
The fact is that such a difference was predictable before our
study: although the MVH value set has been recommended for
use by NICE for more than 20 years, the unusual nature of this
value set, especially the high proportion of negative values and
the wide utility range, are widely known and reported. Studies
undertaken in the United Kingdom using the same protocol in the
years immediately after its publication were unable to replicate its
properties.22 A new value set, whether for the EQ-5D-3L or EQ-
5D-5L, is unlikely to recreate the characteristics of the MVH
value set. Ironically, the EEPRU authors’ concerns about the En-
gland value set implies that the MVH value set will continue to be
used for the foreseeable future, yet it was never subjected to
formal quality assurance.
In the light of the EEPRU review, NICE has recommended
against using the current EQ-5D-5L value set.23 EQ-5D-5L data areinstead recommended to be mapped to the EQ-5D-3L value set.24
A new UK-wide EQ-5D-5L value set is now being commissioned.
We would urge NICE and other HTA bodies to consider the switch
away from old value sets as both inevitable and something that
should not be regarded as a “one off.” No value set should remain
in use for the lengthy period that the MVH value set has. Prefer-
ences change, the composition of the general public changes, and
methods develop and improve. In the future, online data collec-
tion will facilitate more frequent updating of value sets, and we
encourage researchers, both in the United Kingdom and else-
where, to continue to test and develop methods in this area to
facilitate comparisons across value sets developed in different eras
and using different protocols. We hope as much attention is paid
to addressing the transitional challenge for HTA as is being paid to
the value sets themselves.
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